Screening improves survival outcomes in colorectal peritoneal metastases.

Analysis of 2,773 colorectal peritoneal metastasis patients revealed that those diagnosed through screening had significantly better survival rates and more often received curative treatment. Specifically, 7% were screen-detected, with a median overall survival of 20 months compared to 10.8 months for clinically detected patients. Additionally, 28% of screen-detected patients underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy, versus only 14% in the clinically detected cohort, underscoring the advantages of early detection.